All News


Pharmaceutical Technology Europe

After further reviewing data on the H1N1 pandemic vaccines approved in Europe, the EMEA has reaffirmed their balance of benefits and risks in the context of the current H1N1 influenza pandemic. Additionally, the World Health Organization (WHO) has issued an update on the H1N1 situation in Europe.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society for Chemical Manufacturers and Affiliates (SOCMA) provided an update as to its grassroots efforts regarding the recently passed Chemical and Water Security Act of 2009 (HR 2868).

ePT--the Electronic Newsletter of Pharmaceutical Technology

Five percent of consumers across five European countries suspect they may have received a counterfeit prescription, and 1% believe that they definitely have, according to research conducted by ICM on behalf of patient safety communications company Aegate (UK).

Pharmaceutical Technology Europe

Engineers at a UK university claim to have developed technology that can be used in existing chemical reactors to ensure right first time drug crystal formation, which is crucial to their efficacy and the efficiency of pharmaceutical manufacturers' operations.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Following the its $68-billion acquisition of Wyeth (Madison, NJ), Pfizer (New York) Pfizer detailed plans for its global research and development (R&D) network, which includes consolidation of its R&D facilities.

ePT--the Electronic Newsletter of Pharmaceutical Technology

A consortium led by GlaxoSmithKline (UK) intends to deliver a "step change improvement" in pharmaceutical tablet manufacturing in the UK by "substantially" increasing the country's manufacturing efficiency.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Lonza (Basel, Switzerland), the large contract manufacturer of small-molecule and biologic-based active pharmaceutical ingredients (APIs), announced last week a series of cost-cutting measures for the next 12 to 18 months.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Organization for Rare Diseases (EURORDIS) predicts that 100 new designated orphan products will receive marketing authorization between 2009 and 2019, which equates to approximately 10 new products every year.